Certified Global Research Member

Key Questions Answered

Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the key challenges in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major playersâ€™ financial performance.
Evaluate strategies adopted by major players.
Recommendations

Why Choose Market Research Future?

Vigorous research methodologies for specific market.
Knowledge partners across the globe
Large network of partner consultants.
Ever-increasing/ Escalating data base with quarterly monitoring of various markets
Trusted by fortune 500 companies/startups/ universities/organizations
Large database of 5000+ markets reports.
Effective and prompt pre- and post-sales support.

US Oncology Drugs Companies

Oncology Drugs companies are at the forefront of cancer therapeutics. Specializing in the research, development, and manufacturing of anticancer medications, they contribute to the advancement of oncology treatments, offering hope to patients by targeting and combating various forms of cancer.

U.S. Oncology Drugs Key Companies

Latest U.S. Oncology Drugs Companies Update:

Eli Lilly's Jaypirca® (pirtobrutinib) receives FDA approval for the treatment of mantle cell lymphoma, offering a targeted therapy option with promising efficacy and improved tolerability.

BMS's Opdivo® (nivolumab) with Yervoy® (ipilimumab) combination secures FDA approval for the first-line treatment of non-small cell lung cancer (NSCLC) with high PD-L1 expression, extending options for early-stage patients.

Seagen's Tukysa® (tucatinib) in combination with Xeloda® (capecitabine) and Herceptin® (trastuzumab) receives FDA Breakthrough Therapy Designation for HER2-positive metastatic colorectal cancer, potentially accelerating its pathway to market.

Pfizer acquires Global Blood Therapeutics for USD 5.4 billion, gaining access to GBT's portfolio of hemophilia and sickle cell disease treatments, strengthening its presence in rare disease therapeutics.

Merck & Co. enters into a definitive agreement to acquire Veloxis Pharmaceuticals for USD 2.75 billion, acquiring Veloxis's pipeline of oncology candidates, including VX-11e, a PARP inhibitor with potential for pancreatic cancer treatment.

AbbVie and Genmab expand their strategic partnership, focusing on the development and commercialization of bispecific T-cell engagers (BiTEs) for various cancer types, leveraging their combined expertise in antibody engineering and clinical development.

List of U.S. Oncology Drugs Key companies in the market

GlaxoSmithKline PIc.

Novartis AG

Merck & Co. Inc.

Eli Lilly and Company

Amgen Inc.

Bayer

Celgene Corporation

Johnson & Johnson

Pfizer Inc.

US Oncology Drugs Companies

Leading companies partner with us for data-driven Insights

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
	Single User	$ 4,950
	Multiuser License	$ 5,950
	Enterprise User	$ 7,250
Compare Licenses

Tailored for You

Dedicated Research on any specifics segment or region.
Focused Research on specific players in the market.
Custom Report based only on your requirements.
Flexibility to add or subtract any chapter in the study.
Historic data from 2014 and forecasts outlook till 2040.
Flexibility of providing data/insights in formats (PDF, PPT, Excel).
Provide cross segmentation in applicable scenario/markets.